Researchers at St. Jude Children's Hospital have identified a signaling molecule that functions like a factory supervisor to ensure that the right mix of specialized T cells is available to fight infections and guard against autoimmune disease.
The research also showed the molecule, phosphatase MKP-1, is an important regulator of immune balance. Working in laboratory cell lines and mice with specially… Continue
Added by Peter Hofland, PhD on July 22, 2011 at 8:30am —
The Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending the approval of abiraterone acetate (Zytiga®, Janssen-Cilag International NV) for the treatment of metastatic castration resistant prostate cancer. The approval was based on the accelerated regulatory review procedure.… Continue
Added by Peter Hofland, PhD on July 22, 2011 at 8:00am —
Results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by Taiho Pharmaceutical Co., Ltd for metastatic colorectal cancer were presented at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama. (Abstract no. 10428)
TAS-102 is… Continue
Added by Peter Hofland, PhD on July 22, 2011 at 7:30am —
The cobas KRAS mutation test developped by Roche Molecular Systems , a polymerase chain reaction-based diagnostic tool intended for the detection of mutations in codons 12, 13 and 61 of the KRAS gene, is now commercially available in Europe and other countries that recognize the CE mark. The system tests colorectal cancer tissue predictive of individual response to therapy with anti-epidermal growth factor receptor (EGFR) antibody… Continue
Added by Peter Hofland, PhD on July 21, 2011 at 10:30pm —
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Daniel D. Von Hoff, M.D., F.A.C.P. at the 47th annual meeting of the American Society of Clinical Oncology (ASCO). Continue
The drug under investigation, GDC-0941,…
Added by Peter Hofland, PhD on July 20, 2011 at 12:30pm —
The National Institute for Health and Clinical Excellence (NICE) today issued draft guidance on Halaven® (eribulin) for public consultation. The draft guidance does not recommend NHS (National Health Service) funding of eribulin, a treatment for locally advanced or metastatic breast… Continue
Added by Peter Hofland, PhD on July 19, 2011 at 4:30pm —
Oncology treatments are not what they were a decade ago. Drugs that target specific molecular pathways in a cancer cell are being added to or replacing once standard therapies, requiring a new model of patient care. Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions™, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition… Continue
Added by Peter Hofland, PhD on July 19, 2011 at 9:00am —
The use of trastuzumab (Herceptin®,Genentech) chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.
Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, “We clearly now know that these women should get trastuzumab and potentially chemotherapy,… Continue
Added by Peter Hofland, PhD on July 18, 2011 at 11:30am —
Researcher of St. Jude Children's Research Hospital have identified a key immune system regulator, a protein that serves as a gatekeeper in the white blood cells that produce the "troops" to battle specific infections. The findin will provide insight into immune system biology and identify the mechanism that keeps white blood cell activity at a minimum until the specific immune response is needed.… Continue
Added by Peter Hofland, PhD on July 18, 2011 at 7:30am —
The European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on Nektar Therapeutics'application for orphan medicinal product status for the company's lead oncology candidate, NKTR-102, for the treatment of women with ovarian cancer. Continue
Ovarian cancer is the fifth leading cause of cancer deaths among women, accounting for more deaths than any other cancer of the…
Added by Peter Hofland, PhD on July 18, 2011 at 5:00am —
The CLEOPATRA trial, a multicenter international clinical Phase III study, designed to evaluate the efficacy and safety of pertuzumab with trastuzumab and docetaxel vs. placebo with trastuzumab and docetaxel in previously untreated Her2-positive metastatic breast cancer (mBC), has met its primary endpoint: progression-free survival. Continue
Pertuzumab is a monoclonal antibody being studied in early-stage and metastatic HER2-positive breast cancer. It is an…
Added by Peter Hofland, PhD on July 15, 2011 at 8:30am —
The European Commission has granted marketing authorization for denosumab (XGEVA®,Amgen)for the prevention of skeletal-related events or SREs (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of denosumab applies to all 27 European Union member states. The European Commission also granted denosumab an additional year of data and… Continue
Added by Peter Hofland, PhD on July 15, 2011 at 4:30am —
Investigators at the St. Jude Children's Research Hospital reported markedly improved survival of pediatric patients transplanted for high-risk acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) regardless of donor.
The results showed that bone marrow transplant survival more than doubled in recent years for young, high-risk leukemia patients with patients who lacked genetically matched… Continue
Added by Peter Hofland, PhD on July 14, 2011 at 8:00am —
For the tenth consecutive year palliative care in U.S. hospitals has increased for. A new analysis released today by the Center to Advance Palliative Care (CAPC) shows that the number of hospitals with a palliative care team increased from 658 (24.5%) to 1,568 (63.0%)– a steady 138.3% increase from 2000-2009.
Palliative care is specialized medical care focused on relief from the symptoms, pain and stress of… Continue
Added by Peter Hofland, PhD on July 14, 2011 at 7:30am —
Stem cell therapy may restore cognition in patients with brain cancer who experience functional learning and memory loss often associated with radiation treatment, according to a laboratory study published in Cancer Research, a journal of the American Association for Cancer Research.
Charles Limoli, Ph.D., a professor in the… Continue
Added by Peter Hofland, PhD on July 13, 2011 at 12:30pm —
Overall cancer mortality rates are higher for men than women in the United States, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Michael B. Cook, Ph.D., an investigator in the division of cancer epidemiology and genetics at the… Continue
Added by Peter Hofland, PhD on July 12, 2011 at 1:00pm —
According to a study released this week by UCLA's Jonsson Comprehensive Cancer Center, the overwhelming majority of patients with high-grade non-muscle invasive bladder cancer do not receive the recommended treatment and surveillance, leaving them at higher risk for bladder cancer recurrence, progression, and death.
The Bladder Cancer Advocacy Network (… Continue
Added by Peter Hofland, PhD on July 12, 2011 at 11:00am —
The National Cancer Institute (NCI)is collaborating with GNS Healthcare, a subsidiary of Via Science, a healthcare IT company that applies machine learning and simulation technology to optimize patient treatment, to accelerate lung cancer research with a supercomputing platform that can rapidly uncover cause-and-effect mechanisms hidden in huge data sets assembled from… Continue
Added by Peter Hofland, PhD on July 12, 2011 at 5:30am —
A study published in Cancer Cell describes the identification and functional characterization of proteins that confer metastatic and invasive properties to early stage primary melanomas, the most deadly form of skin cancer in humans. The studies were conducted in the laboratories Lynda Chin, M.D., and Ron DePinho, M.D., from the Belfer Institute for Applied Sciences and Dana Farber Cancer Institute, and David Rimm, M.D.,… Continue
Added by Peter Hofland, PhD on July 11, 2011 at 11:00am —
With the increase of negative reports in both print, online and broadcast media, many women around the world wonder if there is a connection between breast augmentation and breast cancer. The U.S. Food and Drug Administration (FDA) continues to support the use of breast implants, as extensive studies have proven their safety.
Earlier this year, the FDA reviewed a possible link between breast implants and a rare… Continue
Added by Peter Hofland, PhD on July 5, 2011 at 5:00am —